Biological/Vaccine: Blood sample and tissue sample
Biological/Vaccine: Blood sample and tissue sample: During the surgery :
Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data
Study summary
Specifically, in this project, the objective will be developped a model to capture imaging-based tumor heterogeneity with multiscale radiomics approach by obtaining the mirror tumor image at in vivo MRI, ex vivo MRI at histology. This imaging model giving a perfect virtual histology tumor representation will be secondary implemented on routine in vivo clinical MRI for early cancer detection and treatment monitoring. Successful completion of this proposal will lead to a comprehensive non invasive characterisation of pancreatic cancer and will be a game changer in patient management.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient aged \>18 2.
* Pathologically proven pancreatic cancer which can beneficiate of upfront surgery or delayed surgery followed by neoadjuvant chemotherapy.
* Negative pregnancy test for women of childbearing potential
* Patients affiliated to a social protection system
* Written informed consent signed before project onset.
Exclusion Criteria:
* presence of metastases,
* Patient who will not have surgery
* Pregnant or breastfeeding women
* Mental or psychological state, physical or legal incapacity preventing participation in the project.
Primary outcome measure(s)
the integration of in vivo and ex vivo MRI with histology and molecular caracteristic in order to increase the pancreatic cancer detection and therapeutic response monitoring — The day of the surgery The diagnostic performance of the radiomic and multiomic algorithm in pancreatic cancer detection and therapeutic response monitoring.
Trial sites (1)
Facility
City
Region
Status
NOUGARET Stephanie
Montpellier
France
Recruiting
More Institut du Cancer de Montpellier - Val d'Aurelle trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
